(Q43038258)

12 November 2017

title

Correlation of protection against Japanese encephalitis virus and JE vaccine (IXIARO(®)) induced neutralizing antibody titers (English)

1 reference

Japanese encephalitis virus

12 November 2017

main subject

0 references

vaccine

1 reference

based on heuristic

inferred from title

Japanese encephalitis

1 reference

1 reference

Yvonne Van Gessel

1

1 reference

12 November 2017

Christoph S Klade

2

1 reference

12 November 2017

Robert Putnak

3

1 reference

12 November 2017

Alessandra Formica

4

1 reference

12 November 2017

Somporn Krasaesub

5

1 reference

12 November 2017

Martin Spruth

6

1 reference

12 November 2017

Bruno Cena

7

1 reference

12 November 2017

Anchalee Tungtaeng

8

1 reference

12 November 2017

Montip Gettayacamin

9

1 reference

12 November 2017

Shailesh Dewasthaly

10

1 reference

12 November 2017

language of work or name

English

0 references

publication date

30 June 2011

1 reference

12 November 2017

number of pages

7

1 reference

based on heuristic

inferred from page(s)

published in

Vaccine

1 reference

12 November 2017

volume

29

1 reference

12 November 2017

issue

35

1 reference

12 November 2017

page(s)

5925-5931

1 reference

Introduction of Japanese encephalitis virus genotype I, India

12 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.062

Adverse events after Japanese encephalitis vaccination: review of post-marketing surveillance data from Japan and the United States. The VAERS Working Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.062

Japanese encephalitis: new options for active immunization

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.062

A purified inactivated Japanese encephalitis virus vaccine made in Vero cells.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.062

Safety and immunogenicity of a Vero-cell-derived, inactivated Japanese encephalitis vaccine: a non-inferiority, phase III, randomised controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.062

Points to consider in the development of a surrogate for efficacy of novel Japanese encephalitis virus vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.062

Nonparametric Estimation from Incomplete Observations

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.062

Correlates of protection induced by vaccination

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.062

A framework for assessing immunological correlates of protection in vaccine trials.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.062

Vaccines: correlates of vaccine-induced immunity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.062

Comparison of protective efficacies of plasmid DNAs encoding Japanese encephalitis virus proteins that induce neutralizing antibody or cytotoxic T lymphocytes in mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.062

Impaired T helper 1 function of nonstructural protein 3-specific T cells in Japanese patients with encephalitis with neurological sequelae

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.062

Antigenic analysis of Japanese encephalitis viruses in Asia by using monoclonal antibodies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.062

Protection against Japanese encephalitis virus strains representing four genotypes by passive transfer of sera raised against ChimeriVax-JE experimental vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.062

Report on a WHO consultation on immunological endpoints for evaluation of new Japanese encephalitis vaccines, WHO, Geneva, 2-3 September, 2004

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.062

Protection against dengue virus by non-replicating and live attenuated vaccines used together in a prime boost vaccination strategy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.062

Effect of genomic variation in the challenge virus on the neutralization titres of recipients of inactivated JE vaccines--report of a collaborative study on PRNT50 assays for Japanese encephalitis virus (JE) antibodies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.062

Antigenic characterization of the live attenuated Japanese encephalitis vaccine virus SA14-14-2: a comparison with isolates of the virus covering a wide geographic area

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.062

Phylogenetic analysis suggests only one serotype of Japanese encephalitis virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.062

Origin and Evolution of Japanese Encephalitis Virus in Southeast Asia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.062

Isolation and genetic characteristics of human genotype 1 Japanese encephalitis virus, China, 2009.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.062

Immunologic correlates of protection against rotavirus challenge after intramuscular immunization of mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.062

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/J.VACCINE.2011.06.062

1 reference

12 November 2017

1 reference